Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
September 10, 2025

Unraveling the Complexities in TNBC Gene Interaction Networks Towards Better Therapeutics.

View Full Paper
Ask AI
Bookmark
Share

Authors

PPPriyanga ParanthamanHKHemaNandini Rajendran KrishnamoorthySVSelvakumar Veluchamy

Discussion

Loading...

Member takes

Overview

Network-based analysis identified key hub proteins in TNBC, suggesting repurposed drugs may target EP300.

Key Points

  • The study identifies hub proteins in triple-negative breast cancer, indicating pathways for targeted therapy.
  • TP53, SRC, and EP300 are among the key hub proteins linked to 5763 interactions in the analysis.
  • Molecular docking and analysis revealed tirbanibulin as a promising candidate for targeting EP300.
  • Repurposing existing FDA-approved drugs against EP300 could significantly impact therapeutic options.

Cite This Study

Paranthaman et al. (2025) studied this question.

synapsesocial.com/papers/68c23b8fb210217d647855cbhttps://doi.org/10.1002/bab.70039
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Identification of Therapeutic Gene Targets in Triple-Negative Breast Cancer: A Hybrid Approach Integrating Semidefinite Programming, Boolean Simulation, and Druggability Analysis2025
  2. 2Therapeutic innovations in triple negative breast cancer: integrating molecular targeting and monoclonal antibody strategies2025 · 5 citations
  3. 3Harnessing TP73‑targeted nintedanib: A novel strategy to halt triple‑negative breast cancer via p53‑PPARα/PI3K‑Akt pathway suppression2025 · 1 citations
  4. 4PROTACs Targeting Molecular Targets in Triple-Negative Breast Cancer2025 · 1 citations
  5. 5Integrative Proteogenomics and Forward Genetics Reveal a Novel Mitotic Vulnerability in Triple-Negative Breast Cancer2025 · 3 citations